Published 17th Jun 2026, 11:45 BST
The firm has announced that its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer, has now been accredited.
Cizzle Biotechnolofy, which is Headquartered in London with a facility in York, worked with its North American licensing partner, Cizzle Bio Inc, on the test.
Professor Dawn Coverley, founder and CSO of Cizzle Biotechnology, said: “After years of work by dedicated scientists here in York, seeing the CIZ1B test finally move from bench to clinic is wonderful.
“We hope that its many practical advantages over other methods, including low cost and the need for very small quantities of blood, will mean that its use can be expanded into rapid and regular screening for lung cancer.”
Cizzle said the accreditation provides a regulated US laboratory route to market for the company’s early lung cancer blood test
It also enables licensed US healthcare providers to order the test, in a move the firm said signifies a commercial launch of the product.
Allan Syms, executive chairman of Cizzle Biotechnology, said: “CLIA accreditation for our CIZ1B biomarker test is a major milestone for the company.
“This was rightly a rigorous process to demonstrate the CIZ1B test is reliable and accurate and can now be used in licensed clinical laboratories as an important tool to help detect lung cancer early and save lives.
“As with any major challenge, it requires expert and determined collaboration to achieve significant breakthroughs in the fight against cancer.
“The outstanding efforts from our team at the University of York along with BIO and the clinical laboratory team at Omni are testament to making this potentially lifesaving test a reality.”